Drug Profile
Neutrophil inhibitory factor-hirulog hybrid
Alternative Names: rNIF-hirulog; TNHHLatest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator Chongqing Fagen Biopharmaceutical
- Developer Chongqing Fagen Biopharmaceutical; West China Hospital Sichuan University
- Class Antithrombotics; Hirudins; Ischaemic heart disorder therapies; Neuroprotectants; Recombinant fusion proteins
- Mechanism of Action CD11b antigen modulators; CD18 antigen modulators; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Stroke
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for phase-I development in Stroke in China (IV, Infusion)